Tekmira Pharmaceuticals this week unveiled new preclinical data from its Ebola and Marburg virus programs, showing that its siRNA-based therapies were effective in non-human primates even when treatment was delayed by as much as 48 hours after infection.

Tekmira also reported its third-quarter financial results, posting a higher net loss amid increased operating expenses, and disclosed that it is poised to receive a milestone payment from Alnylam Pharmaceuticals related to a drug delivery technology licensing arrangement between the firms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.